A triantennary N-acetylgalactosamine (Tri-GalNAcβ) ligand presenting three β-GalNAc residues on a tris-based branched scaffold, equipped with an N-hydroxysuccinimide (NHS) activated ester through a discrete, monodisperse pentaethylene glycol (PEG5) spacer. The NHS ester reacts with primary amines to form stable amide bonds, providing a single-step route to conjugate the Tri-GalNAc ligand onto amine-bearing payloads, antibodies, peptides, proteins, and surfaces. This compound enables the construction of hepatocyte-targeted therapeutics and research tools that exploit the asialoglycoprotein receptor (ASGPR; Ashwell-Morell receptor), which is highly expressed on liver hepatocytes and binds GalNAc-containing ligands with high affinity. The trivalent presentation of GalNAcβ residues engages multiple carbohydrate-recognition domains of ASGPR simultaneously, producing high-avidity binding that substantially exceeds the affinity of monovalent GalNAc ligands and closely mimics the geometry of clinically validated Tri-GalNAc targeting moieties used in approved GalNAc-siRNA therapeutics.